Ligands for LXR and FXR are under clinical development for the treatment of diabetes mellitus, high cholesterol, and obesity; and it is therefore important to balance their beneficial metabolic effects against their possible side effects on platelet reactivity and function. The gene discussed is NR1H4; the disease is Obesity.